CBD showed antiseizure effects across multiple epilepsy subtypes beyond the three it is officially approved for, according to a multicenter retrospective study.
Neurologists, epilepsy patients, caregivers, and pharmaceutical researchers.
Beyond 3 approvalsCBD showed efficacy across epilepsy subtypes beyond Dravet, Lennox-Gastaut, and TSC
What the researchers found
Cannabidiol demonstrated efficacy and tolerability across various epilepsy syndromes beyond Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, suggesting broader therapeutic potential.
Why it matters
CBD is only approved for three specific epilepsy syndromes, but many patients with other forms of treatment-resistant epilepsy use it off-label. Real-world evidence helps justify expanded research and access.
The numbers in context
CBD is approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. This multicenter retrospective study analyzed efficacy across additional epilepsy subtypes.
How the study worked
Retrospective multicenter study analyzing real-world CBD treatment outcomes across various epilepsy subtypes.
Who was studied
Patients with various epilepsy subtypes treated with cannabidiol across multiple medical centers.
What this study cannot tell us
Retrospective design introduces selection bias; lack of placebo control limits efficacy conclusions; dosing protocols likely varied across centers.
How to read the evidence
Retrospective multicenter data provides moderate real-world evidence; prospective trials needed for regulatory expansion.
When this study was published
Recent real-world evidence study reflecting growing clinical experience with pharmaceutical CBD.
The bigger picture
This study supports the growing body of evidence that CBDs antiseizure mechanisms may be broadly applicable, potentially benefiting the large population of patients with treatment-resistant epilepsy who lack effective options.
Replication
Consistent with smaller case series and observational studies showing CBD efficacy beyond approved indications.
Funding
Not specified
Conflicts of interest
Not specified
Questions still open
- Which epilepsy subtypes responded best to CBD?
- What dosing protocols were most effective?
- Should regulatory approvals be expanded based on real-world evidence?
Read the original research
Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study.
Epilepsia open, 8(2), 360-370
Citation
Kühne, Fabienne; Becker, Lena-Luise; Bast, Thomas; Bertsche, Astrid; Borggraefe, Ingo; Boßelmann, Christian Malte; Fahrbach, Jörg; Hertzberg, Christoph; Herz, Nina A; Hirsch, Martin; Holtkamp, Martin; Janello, Christine; Kluger, Gerhard Josef; Kurlemann, Gerhard; Lerche, Holger; Makridis, Konstantin L; von Podewils, Felix; Pringsheim, Milka; Schubert-Bast, Susanne; Schulz, Juliane; Schulze-Bonhage, Andreas; Steinbart, David; Steinhoff, Bernhard J; Strzelczyk, Adam; Syrbe, Steffen; De Vries, Heike; Wagner, Christiane; Wagner, Johanna; Wilken, Bernd; Prager, Christine; Klotz, Kerstin A; Kaindl, Angela M. (2023). Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study.. Epilepsia open, 8(2), 360-370. https://doi.org/10.1002/epi4.12699